

DAY 1 – Wednesday, February 08 <sup>th</sup>	
09:00	Door Opening and Event Registration
09:30-09:40	<b>TEG Welcome Address</b> <b>Chairman's Opening Address</b> <b>Prof. Dr. Thomas Friedli</b> , Chair of Production Management, <b>University of St. Gallen, Switzerland</b>
09:40-10:20	<b>Keynote Opening Presentation</b> <b>Striving for Best - How to become the Leader in Pharmaceutical Production</b> <ul style="list-style-type: none"> <li>Defining and understanding "best"</li> <li>Success factors for excellence initiatives</li> <li>Summary and outlook</li> </ul> <b>Prof. Dr. Thomas Friedli</b> , Chair of Production Management, <b>University of St. Gallen, Switzerland</b>
10:20-10:40	<i>Networking Coffee Break and Vendor Viewing</i>
10:40-11:20	<b>Client Case Study Presentation</b> <b>Re-thinking the Pharmaceutical Distribution Model for South Central Europe</b> <ul style="list-style-type: none"> <li>Innovative solutions in Pharma logistics</li> <li>Lessons learned from setting up a new hub</li> <li>Future optimization possibilities</li> </ul> <b>Zoltán Menyhárt</b> , Vice President of Operations, COO, <b>CEMELOG, Hungary</b> <b>Dániel Buzási</b> , Head of Distribution - Central and Eastern Europe, <b>AstraZeneca</b>
11:20-11:40	<i>Networking Coffee Break and Vendor Viewing</i>
11:40-12:20	<b>Case Study Presentation</b> <b>110 Years of Gedeon Richter - A Hungarian Pharmaceutical Company</b> <ul style="list-style-type: none"> <li>Brief history of Gedeon Richter and representations in the world (commercial, affiliate companies, acquisitions)</li> <li>Richter as a vertically integrated innovative multinational company</li> <li>R&amp;D activities, facilities, the new biotechnology plant in Debrecen, and academic co-operations</li> <li>Look into the future</li> </ul> <b>Prof. Dr. Ádám Vas</b> , Senior Research Adviser, <b>Gedeon Richter Plc</b>
12:20-13:20	Lunch in the Grand Ballroom and Vendor Viewing
13:20-14:00	<b>Case Study Presentation</b> <b>Win - Win Game - Universities and Pharma Industry together</b> <ul style="list-style-type: none"> <li>Labour market needs should meet education output to ensure economical development of a country</li> <li>Ensuring financial background is not enough: knowledge is a bottleneck also</li> <li>Sharing experience is advantageous for everyone</li> <li>Close cooperation instead of do-it-yourself results in business success</li> </ul> <b>Mária Majorné Kelsánszky</b> , Human Resource Director, <b>TEVA, Hungary</b>
14:00-14:20	<i>Networking Coffee Break and Vendor Viewing</i>
14:20-15:00	<b>Client Case Study Presentation</b> <b>Operational Excellence in Pharmaceutical Manufacturing Plants</b> <ul style="list-style-type: none"> <li>Optimizing the production &amp; packaging lines by reducing downtimes, changeovers and waste</li> <li>Visualizing, analyzing and optimizing every aspect of the processes</li> <li>Avoiding failures &amp; providing the operators a comprehensive alarm response management tool</li> <li>Meanwhile sticking to FDA's 21 CFR Part 11</li> </ul> <b>Péter Bóna</b> , Sales and Marketing Director, <b>Com-Forth - GE IP, Hungary</b>
15:00-15:20	<i>Networking Coffee Break and Vendor Viewing</i>
15:20-16:00	<b>Presentation</b> <b>Prevention of the Entry of Supply Chain of Falsified Products – Impact of the New European Legislation</b> <ul style="list-style-type: none"> <li>Falsified, substandard and illegal medicinal products, active substances and excipients</li> <li>Complex, hardly transparent supply chains</li> <li>Production shift to third countries</li> <li>New manufacturing site and distribution chain verification measures</li> <li>Product authenticity verification</li> <li>Solution or hurdles?</li> </ul> <b>Prof. Dr. Tamás L. Paál</b> , Senior Adviser, <b>National Institute for Quality- and Organizational Development in Healthcare and Medicines, Hungary</b>
16:00-16:20	<i>Networking Coffee Break and Vendor Viewing</i>

16:20-17:00	<p><b>Panel Discussion - How to Manage the Complexity of the Supply Chain Network? – How to Keep it Simple?</b>  <b>Prof. Dr. Tamás L. Paál</b>, Senior Adviser, <b>National Institute for Quality- and Organizational Development in Healthcare and Medicines, Hungary</b>  <b>Wojtek Kisielnicki</b>, Supply Chain Director, <b>Polpharma Group, Poland</b>  <b>Zoltán Menyhárt</b>, Vice President of Operations, COO, <b>CEMELOG, Hungary</b>  <b>Dr. Péter Lakatos</b>, Member of Presidency, <b>Hungarian Logistics Association (HLA)</b> &amp; Head of the Teva Logistic Center, <b>TEVA, Hungary</b></p>
17:00-17:20	<i>Networking Coffee Break and Vendor Viewing</i>
17:20	<p><b>Cocktail Reception – Welcome Speech by</b>  <b>Dr. Sergei Sur</b>, R&amp;D Director, <b>Arterium Corporation, Ukraine</b></p>

## DAY 2 – Thursday, February 09<sup>th</sup>

09:00	Door opening
09:30-10:10	<p><b>Opening Keynote Presentation</b>  <b>Development, Clinical Trials and Registration of New Drugs in CIS Countries</b></p> <ul style="list-style-type: none"> <li>• Short review of CIS pharmaceutical markets: Size, developments, potential etc.</li> <li>• Current situation and developing of regulatory requirements for development, CT and registration of drugs in CIS countries</li> <li>• Challenges, problems and practical experience in development, CT and registration of new drugs in CIS countries</li> </ul> <p><b>Dr. Sergei Sur</b>, R&amp;D Director, <b>Arterium Corporation, Ukraine</b></p>
10:10-10:30	<i>Networking Coffee Break and Vendor Viewing</i>
10:30-11:10	<p><b>Presentation</b>  <b>Competitive Environment within High Value Generic Anti-infective API and Injectables</b></p> <ul style="list-style-type: none"> <li>• Regional differences within quality process requirements</li> <li>• Manufacturing practices and collateral risks to the general public health</li> </ul> <p><b>Attila Mile</b>, General Manager, <b>Xellia Pharmaceuticals Budapest</b>  <b>John Stewart</b>, Site Manager, <b>Xellia Pharmaceuticals Copenhagen</b></p>
11:10-11:30	<i>Networking Coffee Break and Vendor Viewing</i>
11:30-12:10	<p><b>Case Study Presentation</b>  <b>The Six Sigma Approach to Quality Improvement in the Pharmaceutical Industry</b></p> <ul style="list-style-type: none"> <li>• Advanced data mining techniques to enhance process understanding</li> <li>• Smart study designs that minimize the effort of experimentation</li> <li>• Translation of statistical findings into actionable solutions</li> </ul> <p><b>Dr. Reinhard Ilk</b>, Six Sigma Black Belt, Quality Assurance, <b>Baxter, Austria</b></p>
12:10-13:10	Lunch in the Grand Ballroom and Vendor Viewing
13:10-13:50	<p><b>Case Study Presentation</b>  <b>Business Process Excellence – Lean Transformation</b></p> <ul style="list-style-type: none"> <li>• Implementation of Business Process Excellence in a global production network</li> <li>• Execution of Local Lean Transformations in Production Plants</li> <li>• Key components and factors for successful transformations</li> </ul> <p><b>Dr. Jens Scheibner</b>, Executive Director Pharma Operations Biberach, Launch &amp; Production Site Germany, <b>Boehringer Ingelheim, Germany</b></p>
13:50-14:10	<i>Networking Coffee Break and Vendor Viewing</i>
14:10-14:50	<p><b>Presentation</b>  <b>The Status of Biotechnology in Hungary</b>  <b>Ernő Duda</b>, President of <b>HBA</b> &amp; CEO of <b>SOLVO Biotechnology</b></p>
14:50-15:10	<i>Networking Coffee Break and Vendor Viewing</i>
15:10-15:50	<p><b>Closing Keynote Presentation</b>  <b>Major R&amp;D Focus of the Hungarian Government – With regards to Pharma Aspects</b></p> <ul style="list-style-type: none"> <li>• The Pharma industry in the global market - Major characteristics</li> <li>• Problems with global EU leadership with regard to Pharma industry – Major competitiveness challenges</li> <li>• Future opportunities: HORIZON2020 – How to enhance the active participation of Pharma industry, e.g. in AHA pilot programme</li> <li>• Pharma industry in Hungary - Major achievements</li> <li>• Support to the Pharma industry in Hungary:             <ol style="list-style-type: none"> <li>1. Financing in 2012 - Coherence in regulation (health policy, competitiveness including R&amp;D, austerity)</li> <li>2. R&amp;D specific tender schemes targeting the Pharma industry</li> <li>3. Recently introduced institutional development - Ex-ante certification of R&amp;D activities</li> </ol> </li> </ul> <p><b>Dr. Antal Nikodémus</b>, Director General for R&amp;D and Innovation, <b>Ministry for National Economy, Hungary</b></p>



**PHARM Connect Congress 2012**

08 – 09 February 2012 | CORINTHIA Grand Hotel Royal, Budapest, Hungary | [www.pharmconnect.eu](http://www.pharmconnect.eu)

15:50-16:00	<b>Chairman's Closing Remarks</b> <b>Prof. Tamás L. Paál</b> , Senior Adviser, <b>National Institute for Quality- and Organizational Development in Healthcare and Medicines, Hungary</b>
15:20-18:30	<b>Excursion</b> to the <b>TEVA Logistic Center</b> in Gödöllő (near Budapest)
16:00-19:00	<b>Plant Excursion</b> to the <b>Sanofi site of Pharmaceutical Core Solids division</b> in Veresegyház (near Budapest)